PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
PDS Biotechnology CorporationNASDAQ: PDSB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $7.35M (cash outflow) fell 13.4% year over year, behind the +53055.5% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +845.2% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$23.04M (-99.9%) for the fiscal year ending Dec 2026, a slowdown from the +91618.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.35M-100.0% QoQ
- Last fiscal yearDec 2025
- -$34.5B+91618.0% YoY
- LTMMar 2026
- $18.8B+53055.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.4% | -25.5% | -12.1 pp |
| 1 year | +91618.0% | -99.9% | -91718.0 pp |
| 3-year CAGR | +845.2% | -91.7% | -936.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (34.5B) USD
- Year-over-year change
- -91618.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.5B) | -91618.0% |
| FY2024 | 2024-12-31 | (37.61M) | +12.4% |
| FY2023 | 2023-12-31 | (42.94M) | -5.1% |
| FY2022 | 2022-12-31 | (40.85M) | -141.5% |
| FY2021 | 2021-12-31 | (16.92M) | — |
Net Income vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 net income of $18.8B is the largest of the 6 companies compared; the peer median is $31.3M.
- Its year-over-year change of +53055.5% is the highest of 6, against a peer median of +40.8%.
- Over three fiscal years its annual growth of +845.2% compares with a peer median of +18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.8B | +53055.5% | +845.2% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $58.75M | -23.5% | +26.3% | — |
| LTM Mar 2026 | $40.92M | +40.8% | +944.4% | — | |
| LTM Mar 2026 | $31.3M | -42.4% | -26.5% | 58.5% | |
| LTM Jun 2026 | $11.31M | +127.6% | +0.9% | 32.2% | |
| LTM Mar 2026 | $4.41M | +110.8% | +18.9% | — | |
| Peer median (excluding PDSB) | $31.3M | +40.8% | +18.9% | 45.4% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5B) |
| Depreciation & Amortization | 5.36K | 86 | 17.36K | 21.11K | 1.55B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.11M | 5.2M | 7.61M | 6.85M | 4.11B |
| Change in Working Capital | 75.82K | 4.47M | (199.28K) | (5.75M) | (382.97K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (105.82K) | (90.12K) | 5.76M | (5.3M) | 1.89M |
| Other Working Capital | 181.64K | 4.57M | (5.96M) | (453.77K) | (2.27M) |
| Other Non-Cash Items | 241.03K | 5.47M | 1.87M | 1.46M | 1.08B |
| Operating Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.03M) | (27.75B) |
| Capital Expenditures | 0 | 0 | 0 | (29K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (29K) | 0 |
| Debt Repayment | 0 | 25M | (59.3K) | (3.18M) | (7.56M) |
| Common Stock Issued | 48.54M | 9.86M | 16.13M | 22.6M | 20.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 344.13K | (568.87K) | 308.94K | 774.09K | 12.76B |
| Financing Cash Flow | 48.89M | 34.29M | 16.38M | 20.19M | 12.77B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 36.4M | 8.58M | (17.26M) | (14.87M) | (14.98B) |
| Free Cash Flow | (12.49M) | (25.71M) | (33.64M) | (35.06M) | (27.75B) |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.